EM
Encore MedicalEncore Medical develops transcatheter septal occlusion devices to repair structural heart defects like patent foramen ovale (PFO).
2 Pulse stories
OB
Ollin BiosciencesClinical-stage biopharmaceutical company developing best-in-disease therapies for vision-threatening eye diseases, including a VEGF/Ang2 bispecific antibody in Phase 3 for DME and wet AMD.
2 Pulse stories
Total Raised
$430M
Encore MedicalOllin Biosciences
Last ValuationNot disclosed
Biotech
Sector
Biotech
2017
Founded
2023
Eagan, Minnesota
HQ
Chicago, Illinois
Public (EMI)
Status
Private
Encore Medical investors
No investors on record.
Ollin Biosciences investors
ARCH Venture PartnersTCGX (TCG Crossover)Andreessen HorowitzMubadala CapitalMonograph CapitalBlackstone Multi-Asset InvestingCommodore CapitalRA Capital Management
Data from Value Add Pulse coverage and company research — see the full threads for Encore Medical and Ollin Biosciences.